"uuid:ID","id","rationale","instanceType","versionIdentifier"
"650c5201-32ef-431a-921e-679e65d59ef6","StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion","2"
